The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.

Bisphosphonates are effective in the management of bone disease in patients with multiple myeloma and recent reports have suggested that they may also have an anti-tumour activity. In support of this, we have previously demonstrated that bisphosphonates can induce myeloma cell apoptosis in vitro; ho...

書誌詳細
主要な著者:	Shipman, C, Vanderkerken, K, Rogers, M, Lippitt, J, Asosingh, K, Hughes, D, Van Camp, B, Russell, R, Croucher, P
フォーマット:	Journal article
言語:	English
出版事項:	2000

類似資料

Bisphosphonates--mechanisms of action in multiple myeloma.
著者:: Shipman, C, 等
出版事項: (2000)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
著者:: Croucher, P, 等
出版事項: (2003)

Bisphosphonates and in vivo models of multiple myeloma - Reply
著者:: Shipman, C, 等
出版事項: (2001)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
著者:: Vanderkerken, K, 等
出版事項: (2003)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
著者:: Croucher, P, 等
出版事項: (2001)

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.
著者:: Shipman, C, 等
出版事項: (1997)

The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
著者:: Shipman, C, 等
出版事項: (1998)

Anti-tumour activity of bisphosphonates in human myeloma cells.
著者:: Shipman, C, 等
出版事項: (1998)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
著者:: Croucher, P, 等
出版事項: (2000)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
著者:: Croucher, P, 等
出版事項: (2001)

Osteoprotegerin and the development of myeloma bone disease
著者:: Croucher, P, 等
出版事項: (2004)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
著者:: Croucher, P, 等
出版事項: (2002)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
著者:: Croucher, P, 等
出版事項: (2001)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
著者:: Croucher, P, 等
出版事項: (2002)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
著者:: Shipman, C, 等
出版事項: (2000)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
著者:: Shipman, C, 等
出版事項: (2002)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
著者:: Mueller, G, 等
出版事項: (2004)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
著者:: Mueller, G, 等
出版事項: (2004)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
著者:: Shipman, C, 等
出版事項: (2002)

Nitrogen-containing bisphosphonates induce apoptosis in human bone marrow-derived myeloma cells in vitro by inhibiting protein prenylation.
著者:: Gordon, S, 等
出版事項: (1999)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
著者:: Edwards, C, 等
出版事項: (2007)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
著者:: De Leenheer, E, 等
出版事項: (2004)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
著者:: Shipman, C, 等
出版事項: (2000)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
著者:: De Leenheer, E, 等
出版事項: (2002)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
著者:: Croucher, P, 等
出版事項: (2003)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
著者:: Locklin, R, 等
出版事項: (2005)

The bisphosphonate-ester apornine does not act by inhibiting protein prenylation, but enhances the effects of lovastatin on myeloma cells
著者:: Roelofs, A, 等
出版事項: (2006)

Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment
著者:: Richard Derman, 等
出版事項: (2009-09-01)

Osteoblasts protect multiple myeloma cells from T-cell-induced apoptosis
著者:: Locklin, R, 等
出版事項: (2007)

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
著者:: Liesbeth Bieghs, 等
出版事項: (2010-01-01)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
著者:: Shipman, C, 等
出版事項: (2002)

The Effectiveness of Zoledronic Acid and Ibandronic Acid in Delaying Skeletal-Related Events in Multiple Myeloma in Indonesia
著者:: Nutrisia Aquariushinta Sayuti, 等
出版事項: (2020-09-01)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
著者:: Shipman, C, 等
出版事項: (2003)

Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
著者:: Clive Henry Buckle, 等
出版事項: (2012-01-01)

Administration of bisphosphonate (ibandronate) impedes molar tooth movement in rabbits: A radiographic assessment
著者:: V Venkataramana, 等
出版事項: (2014-01-01)

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
著者:: Jagdev, S, 等
出版事項: (2001)

NE10790, a phosphonocarboxylate analogue of risedronate, induces human myeloma cell apoptosis in vitro
著者:: Roelofs, A, 等
出版事項: (2004)

Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment.
著者:: Locklin, R, 等
出版事項: (2007)

P948: REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA
著者:: Maria Nieves Lopez Muñoz, 等
出版事項: (2023-08-01)

Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients
著者:: Blum Christina, 等
出版事項: (2010-07-01)